Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2472

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2472
---
believe institutions and their researchers will prefer Ocean Biomedical to launching a startup because Ocean Biomedical eliminates the
challenge of needing to raise capital and hire a team, and provides a greater share in the upside. Likewise, we believe Ocean Biomedical
will be a preferred choice as opposed to licensing to large pharmaceutical companies because receiving a percentage of any economic value,
regardless of how it is derived, is often more attractive than relying on fixed milestone payments or single-digit royalties.

We
believe our approach will give us preferred access to innovations at research universities and medical centers, and that this in turn
will benefit our shareholders.

Our
Pipeline Funnel Process

Our
core competencies for acquiring and developing pipeline programs include: (1) identifying, assessing and selecting inventions and technologies
(from research universities and medical centers) that we may directly or indirectly license and commercialize; (2) in-licensing selected
inventions and technologies; and (3) developing those inventions and technologies into potential therapeutic products aimed at addressing
unmet medical needs.

Step
One: New Program Identification, Assessment and Selection

Our
close relationships with research universities and medical centers, along with their individual researchers, technology transfer offices,
accelerator programs and entrepreneurship centers, provide us with access to biomedical inventions and technologies that we may directly
or indirectly license and commercialize. Our multi-disciplinary Opportunity Assessment Committee, or OAC, is responsible for new program
identification, assessment and selection – and for ensuring adherence to our due diligence process. The OAC is comprised of Dr.
Jonathan Kurtis (Scientific Co-founder), Michelle Berrey (Interim Chief Executive Officer), and Jolie Kahn (Chief Financial Officer).
The OAC applies our disciplined and rigorous due diligence process to identify, assess quantitatively, and select those inventions and
technologies based on criteria we believe ensures that each asset selected to enter our pipeline is consistent with our mission and commercialization
objectives. Our criteria are listed below, and we score and weigh each criterion through a combination of data analytics, experience
and judgment.

    ●
    Robust
    and verifiable science that can lead to predictable outcomes

    ●
    Well-characterized
    mechanisms with potential to be disease modifying

    ●
    Development
    path with timely and achievable milestones / value inflection points

    ●
    Solid
    and dominating intellectual property / patent position

    ●
    Knowledge
    transfer assuredness (inventors available and approachable)

    ●